Journey Medical Corporation (DERM)
Nasdaq · Healthcare · Drug Manufacturers - Specialty & Generic
$6.69+1.21%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $189M
- 52-week range
- $4.31 – $9.56
- 52-week change
- −12.45%
- EPS (trailing)
- −$0.22
- Analyst rating
- 1.0 Strong buy
- Next earnings
- Nov 11, 2026
Fiscal year to Dec 2025
- Revenue
- $61.9M (+10.20%)
- Net income
- −$11.4M
- Operating margin
- −13.2%
- Diluted EPS
- −$0.47
From the company’s annual report on SEC EDGAR.
About Journey Medical Corporation
Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc.
Headquarters: Scottsdale, United States · 58 employees · journeymedicalcorp.com